The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Localization of the primary tumor (LPT) and maintenance strategies after first line oxaliplatin (Ox), fluoropyrimidine (FP), and bevacizumab (Bev) in metastatic colorectal cancer (mCRC): Results from the AIO 0207 trial.
 
Anke C. Reinacher-Schick
Honoraria - Amgen; Baxalta; Celgene; Merck Serono; Pfizer; Roche; Sanofi
Consulting or Advisory Role - Amgen; Baxalta; Merck Serono; Pfizer; Roche; Sanofi; SERVIER
Research Funding - Celgene (Inst); Roche (Inst); Sanofi (Inst)
 
Stefanie Noepel-Duennebacke
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Ipsen; Roche; Takeda
 
Jan Hertel
No Relationships to Disclose
 
Andrea Tannapfel
No Relationships to Disclose
 
Dirk Arnold
Honoraria - Bayer; Merck Serono; Roche/Genentech; SERVIER; TERUMO
Consulting or Advisory Role - Bayer; Biocompatibles; Helsinn Therapeutics; Merck Serono; Roche; Servier; Terumo
Research Funding - Roche/Genentech; Sanofi
Travel, Accommodations, Expenses - Bayer; Merck Serono; Roche/Genentech
 
Axel Hinke
Honoraria - Roche
 
Susanna Hegewisch-Becker
Consulting or Advisory Role - Lilly; Merck
Research Funding - Lilly; MOLOGEN; Roche
Travel, Accommodations, Expenses - Merck